AnaBios News


VP of R&D Najah Abi-Gerges Named Associate Editor of Frontiers in Physiology

Najah Abi-Gerges, Ph.D., Vice President of Research & Development at AnaBios, was recently named a new Associate Editor of the Cardiac Electrophysiology section of Frontiers in Physiology, the second most-cited journal in its field with more than 200,000 citations. Dr. Abi-Gerges holds a MSc in Physiology and Pharmacology from the University of Poitiers (France) and a Ph.D. in Cardiac Physiology from Paris XI University (France). Prior to joining AnaBios, Dr. Abi-Gerges was involved in drug discovery programs at AstraZeneca. With over 17 years in the pharmaceutical industry, he is an innovative leader, having made substantial contributions to drug approvals, [...]

September 29th, 2022|

AnaBios Announces Winner of 2nd Annual Translational Research Grant

AnaBios is pleased to announce that University of Florence professor Romina Nassini, BSc, Ph.D., is the winner of our second annual Translational Research Grant Award. Dr. Nassini will obtain up to $15,000 in AnaBios’ high-quality human tissue samples to study different expressions of proinflammatory mediator receptors in the human peripheral and central nervous systems. Dr. Nassini is a scientist whose research interest focuses on the identification of new activators and inhibitors of TRP channels and the molecular and translational aspects of these mechanisms. She has contributed to the identification of pathways by which inflammatory mediators signal to sensory [...]

July 29th, 2022|

AnaBios Further Expands Business Development Team with Hiring of Dr. Blake Anson

SAN DIEGO, CA – June 7, 2022 – AnaBios is pleased to announce the hire of Blake Anson, Ph.D., as Vice President of Business Development. In this new role, Dr. Anson will contribute to AnaBios’ global growth of its contract research outreach. Dr. Anson joins AnaBios from Stemonix (now part of Vyant Bio), where he was VP of Scientific Affairs and Partnering. “We are really excited to have Blake join our growing business development team,” said Chris Mathes, Ph.D., M.B.A., Chief Commercial Officer of AnaBios. “Blake is well-known throughout the world in the arena of human cell-based preclinical drug discovery [...]

June 14th, 2022|

AnaBios Closes Financing with Ampersand Capital Partners

SAN DIEGO, CA – June 7, 2022 – AnaBios Corporation, a leading preclinical contract research organization (CRO) that focuses on translational research with unique capabilities to measure drug activity directly in human tissue, today announced an investment from Ampersand Capital Partners, a private equity firm specializing in growth equity investments in the life sciences and healthcare sectors. “AnaBios is thrilled to partner with Ampersand to elevate our business in the growing pharma industry,” said Dr. Andre Ghetti, CEO of AnaBios. “These funds will be used to strategically expand our business and grow our capabilities in a variety of therapeutic areas [...]

June 7th, 2022|

Q&A: Meet Daniel Da Costa, New European Director of Business Development

How long have you worked in the life sciences industry and why did you choose this field?  I started my career in the life sciences industry back in 2013 through an entrepreneurship experience.  I chose this field following my PhD as a natural way to bridge science and marketing. I am a scientist by training, and I tend to entertain my natural curiosity for the world through science. I believe science is the perfect way to understand the world surrounding us and push the boundaries of our current knowledge. Being part of the life sciences industry is a way to [...]

May 25th, 2022|

AnaBios, Georgia Tech Team Advance to Top Three in NCATS ASPIRE Reduction-to-Practice Challenge

SAN DIEGO, CA – May 5, 2022 – AnaBios Corporation is proud to announce that its team of experimental biologists, in partnership with a team of computational scientists from the Georgia Institute of Technology, is among the three finalists for the National Center for Advancing Translational Sciences (NCATS) 2020 ASPIRE Reduction-to-Practice Challenge. The multidisciplinary team, whose project focused on the development of a comprehensive integrated platform for translational innovation in opioid abuse, will receive a $200,000 award for reaching this important milestone in the NCATS competition. Led by principal investigator Jeffrey Skolnick, Ph.D., from Georgia Tech, and co-investigator Andre Ghetti, [...]

May 5th, 2022|

Q&A with Orlando Mendoza, New Business Development Manager

How long have you worked in the life sciences industry and why did you choose this field? I started in 2018 when I initially became interested in this industry because of its importance in developing novel therapeutics and advancing quality of life. In many regards, the life sciences community is a strong web of companies working together towards a common purpose. This is very closely aligned with one of my favorite work ethos, "collaboration, not competition." There is so much the scientific community can learn when it collaborates and I want to contribute to that.  What excites you about working [...]

March 24th, 2022|

AnaBios Introduces High-Quality Human Primary Liver Cells for Preclinical Drug Discovery

SAN DIEGO, CA – March 24, 2022 – Today, AnaBios announced it will start providing high-quality human primary liver cells to pharmaceutical, biotech and academic laboratories to further improve the success of preclinical drug discovery research. Human livers are obtained from ethically consented donors for research purposes. Hepatocyes are then isolated from the liver by the expert team at AnaBios using a proprietary method. High-quality hepatocytes are a critical reagent for successful clinical development, with hepatocyte-based assays helping to define the Absorption, Distribution, Metabolism, Excretion (ADME) profiles of novel drugs. In addition, human primary hepatocytes are essential for understanding the [...]

March 24th, 2022|

AnaBios Announces New Business Development Director in Japan

SAN DIEGO, CA – January 24, 2022 – AnaBios is pleased to announce the hiring of Takashi Hayashi as Business Development Director in Japan. Hayashi has more than 30 years of professional experience at Contract Research Organizations (CROs); over 25 years of research and business experience in non-clinical studies from in vitro rodents to non-human primates; and over 15 years of research and business experience in clinical trials of pharma/biotech products and health/functional foods. Hayashi & Associates is presently involved in: 1) business development consulting, 2) sales of medical imaging and cardiac safety testing for clinical trials, and 3) sales [...]

January 24th, 2022|

NCATS ASPIRE Challenge Update: AnaBios, Georgia Tech University Team Advance to Next Round in Effort to Discover Non-addictive Pain Drug Candidates

SAN DIEGO, CA – October 15, 2021 – The National Center for Advancing Translational Sciences (NCATS) has chosen a multidisciplinary team of computational scientists and experimentalists from AnaBios and the Georgia Institute of Technology as one of four groups to progress to the next round in the 2020 NCATS ASPIRE Reduction-to-Practice Challenge. The winning project of the AnaBios-Georgia Tech team is entitled, “Development of a Comprehensive Integrated Platform for Translational Innovation in Pain, Opioid Abuse Disorder and Overdose.” Led by principal investigator Jeffrey Skolnick, Ph.D., from Georgia Tech and co-investigator Andre Ghetti, Ph.D., Chief Executive Officer of AnaBios, the team [...]

October 15th, 2021|

NIH/NINDS Awards AnaBios with $1.7M Grant to Develop Novel Analgesic for Mixed Inflammatory, Neuropathic Pain States

SAN DIEGO, CA – September 30, 2021 – The National Institute of Neurological Disorders and Stroke (NINDS), part of the the National Institutes of Health (NIH), has awarded AnaBios a $1,734,409 Small Business Innovation Research (SBIR) grant through the Helping to End Addiction Long-term Initiative, or NIH HEAL Initiative, to advance the development of its novel analgesic, ANB-504. The new compound was initially developed using PhaseX®, AnaBios’ unique human-based translational paradigm, which helps overcome the limitations of the current pain drug discovery strategy by generating human-relevant and clinically predictive data at the preclinical stage. AnaBios is developing ANB-504, a lead [...]

September 30th, 2021|

AnaBios Announces Winners of Translational Research Grant Award

AnaBios is pleased to announce that Stanford University researchers David Yeomans, PhD, and Justin Meyerowitz, MD, PhD, are the winners of our first annual Translational Research Grant Award. The Stanford researchers will obtain up to $15,000 in AnaBios high-quality human tissue samples to be used for their project determining the translatability of oxytocin efficacy in human cells compared to data from rodent models. Dr. Yeomans is the Director of Pain Research and Faculty of Anesthesia at Stanford University. His lab primarily focuses on distinguishing the science underlying different types of pain, identifying markers of the different pain types, and developing [...]

July 30th, 2021|
Go to Top